CompletedNot Applicable

Optic Nerve Sheath Diameter in Pre-Eclamptic Parturient Receiving Magnesium Sulfate Combined With Dexmedetomidine

Egypt50 participantsStarted 2023-06-06

Plain-language summary

Dexmedetomidine was reported to effectively reduce cerebral metabolism and ICP by decreasing cerebrospinal fluid pressure in patients with cerebral tumors or head injuries that require craniotomy. However, it was also reported to exhibit no effect on ICP. the effect of MgSO4 associated with dexmedetomidine on ONSD in severely pre-eclamptic parturient has been understudied . Though this study aims to evaluate the effect of dexmedetomidine infusion on raised ICP in severely pre-eclamptic parturients using ocular ultrasonography to determine ONSD as a measure of ICP.

Who can participate

Age range18 Years – 40 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * aged18 to 40 years with * at least 36 weeks gestation * admitted with diagnosis of severe pre-eclampsia and scheduled to receive Magnesium Sulphate therapy before delivery Exclusion Criteria: * Presence of ocular wound or Prior ocular surgery * emergency cases, and evidence of fetal compromise * HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet levels) * Chronic hypertension * Hyperthyroidism, and diabetes mellitus * Presence of pre-existing chronic lung and/or cardiac diseases * Presence of pre-existing chronic renal and/or hepatic diseases * Presence of any chronic diseases of central nervous system. * known allergies to the tested drug.

What they're measuring

Optic nerve sheath diameter (ONSD) measurments following Drug administration

Timeframe: Baseline (before starting MgSO4 therapy) then at 1, 6, 12 and 24 hours postoperative

Trial details

NCT IDNCT05610774

SponsorBenha University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-05-10